MDSpire - Summary
Commentary & Perspectives

"We Need Better Answers in Glaucoma"

Leading 2026 Power Lister Gus Gazzard on collaboration, data quality, and trial design

  • March 31, 2026

  • 5 min

Share

Professor Gus Gazzard, recently recognized in the Ophthalmologist Power List, discusses the widening gap between therapeutic innovation in glaucoma and the capacity for robust testing of these treatments. He emphasizes the need for collaborative networks among clinicians and surgeons, as traditional randomized controlled trials face financial and logistical limitations. Gazzard advocates for registry-based randomized controlled trials and the incorporation of advanced statistical tools like WIN ratios and Fragility Indices to enhance the quality of trial results and improve patient outcomes.

Original Source(s)

"We Need Better Answers in Glaucoma"

  • March 31, 2026

Related Content

Equal Pay in Ophthalmology? Not Yet

A decade of AAMC salary data reveals a persistent gender pay gap in academic ophthalmology—and projects it will never close at senior ranks

IOL Calculation Formulas: What Should the Ophthalmologist Expect？

Matching modern IOL formulas to axial length for optimal outcomes

Metformin’s Potential Role in Posterior Capsule Opacification

Common diabetes therapy reaches intraocular lens tissue and may help limit PCO, says newly published data

  • March 30, 2026

  • 3 min